drugset / Trial / NCT06694324
First-line Treatment of Advanced/unresectable DDLPS
NaSingle-groupOpen-labelTreatment
Summary
Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma
Timeline
- Start
- 2024-12-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | — |